| Company Name: |
Lynnchem |
| Tel: |
86-(0)29-85992781 17792393971 |
| Email: |
info@lynnchem.com |
| Company Name: |
Novachemistry |
| Tel: |
44-20819178-90 02081917890 |
| Email: |
info@novachemistry.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | Daclatasvir Impurity F Basic information |
| Product Name: | Daclatasvir Impurity F | | Synonyms: | Monodes(N-carboxymethyl)valine Daclatasvir;Daclatasvir impurity 14/Monodes(N-carboxymethyl)valine Daclatasvir/N-[(1S)-2-Methyl-1-[[(2S)-2-[5-[4’-[2-[(2S)-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1’-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]propyl]carbamic Acid Methyl Ester;methyl N-[(2S)-3-methyl-1-oxo-1-[(2S)-2-{5-[4-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]butan-2-yl]carbamate;Daclatasvir Impurity 40;Methyl ((S)-3-methyl-1-oxo-1-((S)-2-(5-(4''-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1''-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)butan-2-yl)carbamate;Carbamic acid, N-[(1S)-2-methyl-1-[[(2S)-2-[5-[4'-[2-[(2S)-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]propyl]-, methyl ester;Daclatasvir Impurity F;Daclatasvir Monodes(N-carboxymethyl)valine: N-[(1S)-2-Methyl-1-[[(2S)-2-[5-[4'-[2-[(2S)-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]propyl]carbamic Acid Methyl Ester | | CAS: | 1007884-60-7 | | MF: | C33H39N7O3 | | MW: | 581.71 | | EINECS: | | | Product Categories: | | | Mol File: | 1007884-60-7.mol |  |
| | Daclatasvir Impurity F Chemical Properties |
| Boiling point | 963.0±65.0 °C(Predicted) | | density | 1.239±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 11.22±0.46(Predicted) | | color | White to off-white |
| | Daclatasvir Impurity F Usage And Synthesis |
| Uses | Monodes(N-carboxymethyl)valine Daclatasvir is an impurity of Daclatasvir (D101500); a compound that inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). |
| | Daclatasvir Impurity F Preparation Products And Raw materials |
|